



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

<b>INFORMATION DISCLOSURE STATEMENT</b>		Docket Number: <b>12961/46102</b>	
Application Number <b>10/766,263</b>	Filing Date <b>January 27, 2004</b>	Examiner <b>Z. C. TUCKER</b>	Art Unit <b>1624</b>
Invention Title <b>NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES</b>		Inventor <b>Claus MEESE et al.</b>	

Address to:


**Mail Stop RCE**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SIR:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the enclosed PTO 1449 shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO 1449 is enclosed, unless otherwise noted.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate of this communication is enclosed for charging purposes.

Dated: DECEMBER 8, 2005

By:

  
Joseph A. Coppola (Reg. No. 38,413)

KENYON & KENYON

One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as first class mail  
in an envelope addressed to:

Mail Stop RCE

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450  
on

Date: December 8, 2005

Signature: Chandra Serrano

**CUSTOMER NUMBER 26646**



**SUPPLEMENTAL INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT  
Form PTO-1449**

ATTY. DOCKET NO. <b>12961/46102</b>	APPLICATION NO. <b>10/766,263</b>
APPLICANT <b>Z.C. TUCKER</b>	
FILING DATE <b>January 27, 2004</b>	GROUP <b>1624</b>

**U. S. PATENT DOCUMENTS\***

EXAMINER INITIAL	PATENT/PUBLICATION NUMBER	PATENT/PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	3,446,901	May 27, 1969	G. J. Macclesfield			
	4,988,730	January 29, 1991	Korbonits et al.			
	5,382,600	January 17, 1995	Jonsson et al.			
	5,559,269	September 24, 1996	Johansson et al.			
	5,922,914	July 13, 1999	Gage et al.			
	6,517,864	February 11, 2003	Orup Jacobsen et al.			
	6,630,162	October 7, 2003	Nilvebrant et al.			
	6,713,464	March 30, 2004	Meese et al.			
	6,770,295	August 3, 2004	Kreilgard et al.			
	6,783,769	August 31, 2004	Arth et al.			
	6,809,214	October 26, 2004	Meese			
	6,809,225	October 26, 2004	Donsbach et al.			
	6,858,650	February 22, 2005	Meese			
	6,890,920	May 10, 2005	Richards et al.			
	6,911,217	June 28, 2005	Gren et al.			
	2003/0124179	July 3, 2003	Jacobsen, Lene O. et al.			
	2004/0186061	September 23, 2004	Meese, Claus et al.			
	2005/0004223	January 6, 2005	Slatter, John G. et al.			

\*- copies of U.S. references are not enclosed

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	925 468 (in German, with English translation)	March 21, 1955	DE			YES
	1 216 318 (in German, with English translation)	May 12, 1966	DE			YES
	325 571	July 26, 1989	EP			
	667 852	August 23, 1995	EP			
	1 019 358	July 19, 2000	EP			
	1 077 912	February 28, 2001	EP			
	1 128 819	September 05, 2001	EP			
	624 117	May 27, 1949	GB			
	627 139	July 29, 1949	GB			
	WO 93/23025	November 25, 1993	PCT			
	WO 96/12477	May 02, 1996	PCT			

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	WO 98/03067	January 29, 1998	PCT			
	WO 00/12069	March 09, 2000	PCT			
	WO 00/27364	May 18, 2000	PCT			
	WO 01/34139	May 17, 2001	PCT			

#### OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Abrams et al., "Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder," 1998, Br. J. Urol. 81:801-810
		Anderson et al., "Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence," 1999, J. Urol. 161:1809-1812
		Andersson et al., "Pharmacological treatment of urinary incontinence," in Abrams P., Khoury S., Wein A. (Eds), <u>Incontinence, 2nd International Consultation on Incontinence</u> , Plymouth, Plymbridge Distributors Ltd, UK, Plymouth, 2002, pp 479-511
		Andersson, "Antimuscarinics for treatment of overactive bladder," 2004, Lancet Neurol. 3:46-53
		Andersson & Wein, "Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence," 2004, Pharmacol. Rev. 56:581-631
		Appell et al., "Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study," 2001, Mayo Clinic Proceedings 76:358-363
		Breidenbach et al., "Pharmacodynamic profiling of the novel antimuscarinic drug fesoterodine on rat bladder," 2002, Proceedings of the International Continence Society, 32:449
		Brynne et al., "Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine, 1998, Clin. Pharmacol. Ther. 63:529-539
		Brynne et al., "Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine, and omeprazole," 1999, Br. J. Clin. Pharmacol. 47:145-150
		Brynne et al., "Fluoxetine inhibits the metabolism of tolterodine – pharmacokinetic implications and proposed clinical relevance," 1999, Br. J. Clin. Pharmacol. 48:553-563
		Brynne et al., "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity," 1999, Br. J. Clin. Pharmacol. 48:564-572
		Cawello et al., "Multiple dose pharmacokinetics of fesoterodine in human subjects," 2002, Nauyn-Schmiedeberg's Arch. Pharmacol. 365 (Suppl. 1):428, 2002
		Chancellor et al., "A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate," 2001, Clinical Therapeutics 23:753-760
		Chapple & Udo, "Delay to maximum effect in overactive bladder patients treated with oxybutynin or tolterodine," 2000, European Urology 37(Suppl. 2):84, abstract 335 from the XVth Congress of the European Association of Urology, Brussels, Belgium, April 12-15, 2000
		Chapple et al., "Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a Phase II controlled study," 2004, Proceedings of the International Continence Society, 34:142
		Clemett & Jarvis, "Tolterodine: a review of its use in the treatment of overactive bladder," 2001, Drugs & Aging 18:277-304
		Cole, "Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: A safety update," 2004, Drugs of the Future 29:715-720
		Detroil® package insert, Pharmacia & Upjohn Co., April, 2004
		Diokno et al., "Tolterodine (Detroil®) improves incontinence and nocturia in urological based study," 1999 April, J. Urol. 161 (4 Suppl):256, abstract 987

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Eksstrom et al., "Effects of tolterodine on bladder function in healthy volunteers," Journal of Urology 153(Suppl.):394A, abstract 662 from the 19 <sup>th</sup> Annual Meeting of the American Urological Association, Las Vegas, April 23-28, 1995
		Gillberg et al., "Tolterodine, a new agent with tissue effect selectivity for urinary bladder," 1994, Neurourology and Urodynamics 13:435-436, abstract 60B from International Continence Society 24 <sup>th</sup> Annual Meeting, Prague, Czech Republic, August 1994
		Gillberg et al., "Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists," 1998, European Journal of Pharmacology 349: 285-292
		Hills et al., "Tolterodine," 1998, Drugs 55:813-820
		Jonas et al., "Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation," 1997, World J. Urol. 15:144-151
		Kershen & Hsieh, "Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine," Curr. Urol. Rep. 5:359-367
		Klosa, "Eine Neue Synthese von Diphenylisopropylaminen," 1966, Journal für Praktische Chemie 4:335-340 (in German, with English translation)
		Larsson et al., "Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II safety and efficacy data," 1999, Urology 53: 990-998
		Millard et al., "Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity," 1999, J. Urol. 161:1551-1555
		Modiri et al., "Effect of muscarinic antagonists on micturition pressure measured by cystometry in normal, conscious rats," 2002, Urology 59:963-968
		Naerger et al., "Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders," 1995, Neurourology and Urodynamics 14:524-526, abstract 76 from International Continence Society 25 <sup>th</sup> Annual Meeting, Sydney, Australia, October 1995
		Nilsson et al., "Comparison of a 10 mg controlled release oxybutynin tablet with a 5 mg oxybutynin tablet in urge incontinence patients," 1997, Neurourol. Urodyn. 16:533-542
		Nilvebrant & Sparf, "Receptor binding profiles of some selective muscarinic antagonists," 1988, European Journal of Pharmacology 151:83-96
		Nilvebrant et al., "The in vitro pharmacological profile of tolterodine – a new agent for the treatment of urinary urge incontinence," 1994, Neurourology and Urodynamics 13:433-435, abstract 60A from International Continence Society 24 <sup>th</sup> Annual Meeting, Prague, Czech Republic, August 1994
		Nilvebrant et al., "Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo," 1996, Neurourology and Urodynamics 15:310-311, abstract 34 from the 26 <sup>th</sup> Annual Meeting of the International Continence Society, Athens, Greece, August 27-30, 1996
		Nilvebrant, "Tolterodine and terodilane – different pharmacological profiles," pages 141-142, abstract 181a, from the 27 <sup>th</sup> Annual meeting of the International Continence Society, Yokohama, Japan, September 1997
		Nilvebrant et al. "Tissue distribution of tolterodine and its metabolites: low penetration into the central nervous system," 2000, European Urology 37(Suppl. 2):84, abstract 333 from the XVth Congress of the European Association of Urology, Brussels, Belgium, April 12-15, 2000
		Nilvebrant, "The mechanism of action of tolterodine," 2000, Reviews in Contemporary Pharmacotherapy 11:13-27
		Olsson et al., "Food increases the bioavailability of tolterodine but not effective exposure," 2001, J. Clin. Pharmacol. 41:298-304
		Olsson & Szamosi, "Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder," 2001, Clinical Pharmacokinetics 40:135-143
		Olsson & Szamosi, "Multiple dose pharmacokinetics of a new once daily extended release formulation versus immediate release tolterodine," 2001, Clinical Pharmacokinetics 40:227-235

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Rentzhog et al., "Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study," 1998, Br. J. Urol. 81:42-48
		Sachse et al., "Pharmacodynamics of multiple dose treatment with the novel antimuscarinic drug fesoterodine," 2002, Nauyn-Schmiedeberg's Arch. Pharmacol. 365 (Suppl. 1):413
		Sachse et al., "Safety and pharmacokinetics of the novel bladder-selective antimuscarinic drug fesoterodine in populations of different age or gender," 2002, Proceedings of the International Continence Society, 32:441
		Sachse et al., "Safety and pharmacokinetics of the novel bladder-selective antimuscarinic fesoterodine in populations of different ethnic origin," 2003, Proceedings of the International Continence Society, 33:377
		Sachse et al., "Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine," 2003, Nauyn-Schmiedeberg's Arch. Pharmacol. 367 (Suppl. 1):446
		Sachse et al., "Pharmacodynamics and pharmacokinetics of ascending multiple oral doses of the novel, bladder-selective antimuscarinic fesoterodine," 2003, Eur. Urol. Suppl 2:111
		Sachse et al., "Concomitant food intake does not significantly influence the pharmacokinetics of the novel, bladder-selective antimuscarinic fesoterodine," 2004, Proceedings of the International Continence Society, 34:580
		Sachse et al., "Safety, tolerability and pharmacokinetics of fesoterodine in patients with hepatic impairment," 2004, Proceedings of the International Continence Society, 34:585
		Sachse et al., "Safety, tolerability and pharmacokinetics of fesoterodine after co-treatment with the potent cytochrome P450 3A4 inhibitor ketoconazole," 2004, Proceedings of the International Continence Society, 34:586
		Sachse et al., "Clinical pharmacological aspects of the novel bladder-selective antimuscarinic fesoterodine," 2004, Progrès en Urologie, 14 (Suppl. 3):58
		Stahl et al., "Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity," 1995, Neurol. Urodyn. 14:647-55
		Teuvo et al "Extended release tolterodine compared with immediate release tolterodine for the treatment of overactive bladder," 2000, European Urology 37(Suppl. 2):84, abstract 334 from the XVth Congress of the European Association of Urology, Brussels, Belgium, April 12-15, 2000
		Van Kerrebroeck et al., "Tolterodine once daily: superior efficacy and tolerability in the treatment of the overactive bladder," 2001, Urology 57:414-421
		Van Kerrebroeck et al., "Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder," 1997, Neurol. Urodyn. 16:478-479, abstract no. 91 from the 27th Annual meeting of the International Continence Society, Yokohama, Japan, September 1997
		Versi et al., "Dry mouth with conventional and controlled release oxybutynin in urinary incontinence," 2000, Obstet. Gynecol. 95:718-721
		Wefer et al., "Tolterodine: an overview," 2001, World Journal of Urology 19:312-318

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	